Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff

-- Commercial employee (non-executive) who was hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection is the recipient of this grant --

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum's Board of Directors granted an aggregate of 20,833 inducement restricted stock units ("RSUs") to a commercial non-executive employee who was hired specifically for the launch of ROLVEDON. The award was granted under Spectrum's 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spectrum, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Spectrum, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over three years on the first three anniversaries of the grant date, subject to continued service through each applicable vesting date.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. For additional information on Spectrum please visit www.sppirx.com .

Notice Regarding Forward-looking statements

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including Spectrum's ability to successfully execute across the biopharmaceutical business model, including successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, the possibility that our commercialization efforts may not be successful, our dependence on third parties for manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and ROLVEDON™ are the Spectrum Pharmaceuticals' logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 202   3 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Tom Riga
Chief Executive Officer
949.788.6700
InvestorRelations@sppirx.com

Lisa Wilson
In-Site Communications, Inc.
212.452.2793
lwilson@insitecony.com

News Provided by Business Wire via QuoteMedia

NTR:CA,NTR
The Conversation (0)

Nutrien Reports Second Quarter 2024 Results and Announces Chief Financial Officer Transition

  • Second quarter results supported by increased crop input margins, strong global potash demand, higher fertilizer operating rates and lower operating costs.
  • Mark Thompson appointed Executive Vice President and Chief Financial Officer effective August 26, 2024.

All amounts are in US dollars, except as otherwise noted

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Combine harvester harvests ripe wheat.

Top 10 Phosphate Countries by Production (Updated 2024)

Phosphate is mainly used in the form of fertilizer for crops and animal feed supplements. Only 5 percent of world phosphate production is used for other applications, such as corrosion prevention and detergents.

Demand for phosphate fertilizers had created a US$54.6 billion market by 2023, and that figure is expected to grow at a compound annual growth rate of 5.3 percent through 2030 to reach US$78.4 billion.

"One of the primary factors influencing the worldwide market for phosphate fertilizers is the increasing focus on sustainable agriculture," according to Persistence Market Research. "Phosphate fertilizers, which are widely recognized for their ability to augment soil fertility and enhance crop productivity, are crucial for the pursuit of sustainability objectives in the agricultural industry."

Keep reading...Show less
Tractor on farm field.

9 Phosphate Stocks to Watch (Updated 2024)

Demand for both phosphate and potash fertilizers is anticipated to continue growing as the world’s population increases and the amount of arable land decreases.

The phosphate market is expected to witness a compound annual growth rate of 5.3 percent between 2023 and 2030 to reach US$78.4 billion. Driving this growth will be increasing pressure on global food supply brought on by rising populations and climate change, as well as inflation and downstream costs. Phosphate is also increasingly becoming a sought-after battery material for the electric vehicle industry due to its use in lithium-iron-phosphate (LFP) batteries.

Thankfully, phosphate-mining production around the globe is expected to increase, with the largest areas of growth being Africa and the Middle East. Phosphate mining companies with project developments in Brazil, Kazakhstan, Mexico, Peru and Russia are all expected to contribute to increased phosphate rock production as well.

Keep reading...Show less

Nutrien Announces Release Dates for Second Quarter 2024 Results and Conference Call

Nutrien Ltd. (TSX and NYSE: NTR) announced today plans to release second quarter 2024 results after market close on Wednesday, August 7. Nutrien will host a conference call to discuss its results and outlook at 10:00 a.m. EDT on Thursday, August 8.

Investors can access the call by dialing 1-289-514-5100 or 1-800-717-1738. A webcast of the call can be accessed by visiting Nutrien's website at nutrien.com/investors/events .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Nutrien Prices Offering of an Aggregate of US$1.0 Billion of 3-Year and 10-Year Senior Notes

Nutrien Ltd. (TSX and NYSE: NTR) today announced the pricing of US$400 million aggregate principal amount of 5.200 percent senior notes due June 21, 2027 and US$600 million aggregate principal amount of 5.400 percent senior notes due June 21, 2034 (together, the "senior notes").  The offering is expected to close on or about June 21, 2024, subject to customary closing conditions.  The senior notes, registered under the multi-jurisdictional disclosure system in Canada and the United States, will not be offered in Canada or to any resident of Canada.

Nutrien intends to use the net proceeds from this offering to repay its US$500 million aggregate principal amount of 5.900% senior notes upon their maturity on November 7, 2024, to reduce outstanding indebtedness under its short-term credit facilities, to finance working capital and for general corporate purposes. The senior notes will be unsecured and rank equally with Nutrien's existing senior unsecured debt. The joint book-running managers for the offering are CIBC World Markets Corp., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and RBC Capital Markets, LLC.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Nutrien to Highlight Strategic Priorities and 2026 Targets at Investor Day

Nutrien Ltd. (TSX and NYSE: NTR) today is hosting an Investor Day at the New York Stock Exchange beginning at 10:00 a.m. EDT. At the event, management will detail plans to fortify its leadership position across the ag value chain and position the Company to deliver long-term growth.

"Nutrien operates the most extensive crop inputs and services ecosystem with low-cost upstream production assets, global supply chain capabilities, and the leading downstream retail channel to the farmer. Our differentiated business model is centred on our ability to efficiently produce and distribute the products and services needed in key agriculture markets around the world," commented Ken Seitz, Nutrien's President and CEO.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×